SCHEMBL6724772

SCHEMBL6724772

C[Si](C)(C)CCOC(=O)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3822361 0.87 THRB (0.32)
SCHEMBL10593209 0.83 THRB (0.30)
SCHEMBL10462000 0.81 THRB (0.33)
SCHEMBL14355619 0.81 THRB (0.33)
SCHEMBL154678 0.80
SCHEMBL10757461 0.79
SCHEMBL145422 0.77 THRB (0.53)
SCHEMBL154677 0.77 ALDH1A1 (0.41)
SCHEMBL9666537 0.77 EGLN1 (0.38)
SCHEMBL34343 0.76 THRB (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138242-A1 Dihydropyrimidines and uses thereof MERCK AND CO., INC. 2004-07-15 US disclosed
US-6680323-B2 SELECTIVE ANTAGONISTS FOR HUMAN ALPHA 1A RECEPTORS; BENIGN PROSTATIC HYPERPLASIA; (+)-1-3-((4-(3,4-DIFLUOROPHENYL)-2,5-DIOXO-1,2,5,7-TETRAHYDRO-4H-FURO(3,4 -D)PYRIMIDINE-3-CARBONYL)AMINO)-PROPYL-4-(2-PYRIDYL)-PIPERIDINE SYNAPTIC PHARMACEUTICAL CORPORATION 2004-01-20 US disclosed
EP-1139972-A4 DIHYDROPYRIMIDINES AND USES THEREOF SYNAPTIC PHARMA CORP (US) 2002-03-27 EP disclosed
US-20010041707-A1 Dihydropyrimidines and uses thereof MERCK AND CO., INC 2001-11-15 US disclosed
EP-1139972-A1 DIHYDROPYRIMIDINES AND USES THEREOF SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2001-10-10 EP disclosed
US-6274585-B1 BENIGN PROSTATIC HYPERPLASIA TREATMENT SYNAPTIC PHARMACEUTICAL CORPORATION 2001-08-14 US disclosed
WO-2000037026-A1 DIHYDROPYRIMIDINES AND USES THEREOF SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2000-06-29 WO disclosed